/
DBV Technologies is a late-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. Our therapeutic approach is based on epicutaneous immunotherapy, or EPIT, our proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous p…
The business is unprofitable at the operating level (-2609.23% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 35.8% YoY with margins expanding 199.5pp.
ROIC dropped from -102.23% to -110.84%, capital efficiency is deteriorating. Negative free cash flow of -$122M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$6M
▲ +35.8% YoY
Net Income (TTM)
-$167M
▼ -229.0% YoY
Op. Margin
-2935.08%
▲ +199.5pp YoY
ROIC
-97.84%
▼ -8.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$152M
▼ -14.0% YoY
Op. Cash Flow (TTM)
-$151M
▼ -16.0% YoY
Net Debt
-$223M
Net Cash Position
Cash & Equiv.
$229M
5Y CAGR: -13.0%
Continue Research